Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.81 |
| ▸ | F2 | P00734 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | C1R | P00736 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | KLK1 | P06870 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125184 | 0.90 | ELANE (0.93) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL29456973 | 0.90 | ELANE (0.93) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL29382161 | 0.90 | ELANE (1.00) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL272702 | 0.90 | ELANE (1.00) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL3254378 | 0.88 | ELANE (0.89) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL12212888 | 0.88 | ELANE (0.89) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL273036 | 0.86 | ELANE (0.93) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL271965 | 0.84 | ELANE (0.83) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL29444225 | 0.84 | ELANE (0.83) | ELANEF2NPC1RAB9ARXFP1 | |
| SCHEMBL272287 | 0.84 | ELANE (0.81) | ELANEF2NPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | claimed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | claimed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | claimed |
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | FUJIFILM CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ELANE 353/4885F2 485/4885NPC1 4151/4885 |
| US-20090239982-A1 | Ultraviolet Absorbent and Heterocyclic Compound | CYP2A6, CYP2B6, XPO6 | ELANE 1479/4885F2 102/4885NPC1 1604/4885 |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | ELANE 3009/4885F2 3124/4885NPC1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.